Extended Data Fig. 6: Novel-3 antagomiR showed neuroprotection against ischemic stroke.

a, Illustration of the in vivo experimental design injecting Novel-3 antagomir. b, Representative images and quantitative analysis of Cy3 labeled antagomiR-NC and antagomiR-Novel-3 colocalization with Iba1⁺ MM at 3 days after MCAO (N = 6). Two-tailed unpaired t-test. Data are shown as mean ± SD. c, Representative images of immunostaining showed Iba-1⁺ cells, 3D construction and sholl analysis in the peri-infarct areas of MCAO mice with daily administration of AS-exos and treatment of NC antagomiR or Novel-3 antagomiR (N = 6). Quantitative analysis of microglial density, and morphological changes including solidity, round, branch numbers and lengths, and end-point voxels. Two-tailed unpaired t-test. Data are shown as mean ± SD. d, Representative images and quantitative analysis of Iba-1⁺ microglia with lipid peroxidation marker (4-Hydroxynonenal, 4-HNE) and oxidized DNA marker (8-OHdG) at 3days after MCAO (N = 6). Two-tailed unpaired t-test. Data are shown as mean ± SD. e, Quantitative analysis of behavioral tests as measured by the mNSS, foot fault rate and rotarod test (N = 6). Two-tailed Mann-Whitney U tests and Two-way ANOVA tests for mNSS. Two-way ANOVA tests for foot fault rate and rotarod test. Data are presented as mean ± SD. f, Representative images and quantitative analysis of Nissl staining of MCAO mice with daily administration of AS-exos and treatment of NC antagomiR or Novel-3 antagomiR (N = 6). Black dashed lines indicate the border of infarct area. Dot plots indicated percentage of infarct area of individual mouse in each group. Two-tailed unpaired t-test. Data are presented as mean ± SD.